Drug intelligence / Profile preview

gatifloxacin

Development stage: Approved
Lead developer: Kyorin Pharmaceutical
Modality: Small Molecules
Administration: Intravenous, Ophthalmic, Oral

Overview

Gatifloxacin is a fourth-generation fluoroquinolone antibiotic with broad-spectrum activity against both Gram-positive and Gram-negative bacteria. It works by inhibiting bacterial DNA gyrase and topoisomerase IV, which are essential for DNA replication, transcription, and repair. Developed by Kyorin Pharmaceutical Co., Ltd., it is used to treat various infections, including respiratory and urinary tract infections. Gatifloxacin is noted for its low phototoxicity and minimal toxicity to human cells.

Brand names: ZymarZymaxid
Other names: 加替沙星

Targets

DNA gyraseTopo IV (Bacterial Topoisomerase IV)

Beyond the preview

Go deeper on gatifloxacin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gatifloxacin.

Explore the full profile